Skip to content
Scientists looking at microscope.

Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry

Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.

Mitsui Invests in E12 Ventures, a US-based Venture Capital Fund

Mitsui Invests in E12 Ventures, a US-based Venture Capital Fund

Mitsui & Co., Ltd. (“Mitsui”, Head Office: Tokyo, President and CEO: Kenichi Hori), together with The Norinchukin Bank (President and CEO: Kazuto Oku), Mitsubishi Pencil Company, Limited (President: Shigehiko Suhara), and Nitto Denko Corporation (President: Hideo Takasaki) (hereinafter collectively “the Limited Partners”), announced its capital commitment to E12 Venture Capital Fund I, L.P. (“E12 Fund I”) upon its final closing.

Two people shaking hands

Beigene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.

Back To Top
Search